Q3 performance of MSD! K pharmaceutical's single quarter revenue of US $3 billion in China increased by 90%
-
Last Update: 2019-10-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On October 29, MSD released the Q3 performance report in 2019 In the first three quarters, the global sales revenue was US $34.972 billion, of which the Q3 sales revenue was US $12.4 billion, up 15% year on year Keytruda's global sales in the third quarter were $3.07 billion, up 62% year-on-year, with a total of $7.973 billion in the first three quarters of 2019 Gardasil / Gardasil 9 had global sales of $3044 million in the first three quarters Core drug sales of MSD in the first three quarters of 2019 (US $100 million) In the first three quarters of 2019, the revenue of MSD's China business reached US $2.368 billion, of which the Q3 sales revenue reached US $898 million, an increase of 84% year-on-year, surpassing that of Japan Excluding the adverse effects of foreign exchange, it increased by 90% year-on-year Mainly driven by keytruda and Gardasil / Gardasil 9.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
